LTCR‑H1‑1
Prevention of HCC recurrence post‑liver transplantation
Phase 1Upcoming
Key Facts
Indication
Prevention of HCC recurrence post‑liver transplantation
Phase
Phase 1
Status
Upcoming
Company
About Lion TCR
Pioneering mRNA‑based TCR‑T cell immunotherapy for HBV‑driven liver cancer in Asia.
View full company profile